People who are 30 years old and younger should no longer be given the covid-19 vaccine Nuvaxovid, recommends the Public Health Agency. The background to the decision is that data from Australia has shown an increased incidence of myocarditis and pericarditis in connection with the vaccine, especially in younger people. The vaccine can still be given as a primary dose or top-up dose to people aged 31 and over, according to the Public Health Authority.
In Sweden, approximately 7,000 doses of Nuvaxovid have been given, so it is not a matter of use to any great extent, writes the Public Health Agency.
“We are following the situation closely and are awaiting more data. But anyone who is younger and recently vaccinated with Nuvaxovid need not worry. The risk is very small and you can continue with the next dose with another vaccine,” says Sören Andersson, head of the unit for vaccination program, in a press release.
The decision applies from today, Thursday, and is temporary, the authority writes on its website.